Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Total Liabilities (2019 - 2026)

Opus Genetics has reported Total Liabilities over the past 13 years, most recently at $87.9 million for Q1 2026.

  • Quarterly Total Liabilities rose 262.41% to $87.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $87.9 million through Mar 2026, up 262.41% year-over-year, with the annual reading at $34.9 million for FY2025, 208.94% up from the prior year.
  • Total Liabilities was $87.9 million for Q1 2026 at Opus Genetics, up from $34.9 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $87.9 million in Q1 2026 and troughed at $2.7 million in Q3 2022.
  • The 5-year median for Total Liabilities is $5.8 million (2023), against an average of $15.0 million.
  • Year-over-year, Total Liabilities dropped 28.59% in 2022 and then skyrocketed 404.81% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $2.8 million in 2022, then surged by 46.82% to $4.0 million in 2023, then surged by 179.44% to $11.3 million in 2024, then surged by 208.94% to $34.9 million in 2025, then surged by 151.86% to $87.9 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Total Liabilities are $87.9 million (Q1 2026), $34.9 million (Q4 2025), and $30.2 million (Q3 2025).